Role of Matrix Metalloproteinase-2 in the Development of Atherosclerosis Among Patients with Coronary Artery Disease

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2023 Jul 17

PMID 37457745

Authors

Nazirah Samah

Azizah Ugusman

Adila A Hamid

Nadiah Sulaiman

Amilia Aminuddin

Affiliations

Soon will be listed here.

Abstract

Coronary artery disease (CAD) is a caused by atherosclerotic plaque buildup in the coronary arteries that supply blood and oxygen to the heart. Matrix metalloproteinase (MMP) is a family of zinc-dependent endopeptidase that is involved in various stages of atherosclerosis as demonstrated in and studies. MMP-2 is associated with both stable and unstable atherosclerotic plaque formation. The current review aimed to identify the role of MMP-2 in atherosclerosis development among CAD patients. Literature search was conducted through four online databases and only studies that were published from 2018 until February 2023 were included. The risk of bias was assessed by using the Newcastle-Ottawa Scale. A total of 10,622 articles were initially identified, and only eight studies that fulfilled the selection criteria were included in this review. The results showed that MMP-2 levels and activity were higher in patients with unstable CAD than those with stable CAD and healthy subjects. There was a significant association between MMP-2 levels and cardiovascular disease with MMP-14 levels, which is a pro-MMP-2 activator. In addition, two single nucleotide polymorphisms of the MMP-2 gene (rs243865 and rs243866) were significantly associated with the development of atherosclerosis. In conclusion, MMP-2 plays a crucial role in the development of atherosclerosis among patients with CAD and could be a potential target for CAD therapy.

Citing Articles

Emerging nanoprobes for the features visualization of vulnerable atherosclerotic plaques.

Wang X, Mu D, Liang J, Xin R, Zhang Y, Liu R Smart Med. 2025; 3(4):e20240033.

PMID: 39776593 PMC: 11669784. DOI: 10.1002/SMMD.20240033.

Vascular Extracellular Matrix in Atherosclerosis.

Di Nubila A, Dilella G, Simone R, Barbieri S Int J Mol Sci. 2024; 25(22).

PMID: 39596083 PMC: 11594217. DOI: 10.3390/ijms252212017.

Exploring the Potential of Saphenous Vein Grafts Ex Vivo: A Model for Intimal Hyperplasia and Re-Endothelialization.

Haron N, Ishak M, Yazid M, Vijakumaran U, Ibrahim R, Raja Sabudin R J Clin Med. 2024; 13(16).

PMID: 39200916 PMC: 11355503. DOI: 10.3390/jcm13164774.

Unveiling TIMPs: A Systematic Review of Their Role as Biomarkers in Atherosclerosis and Coronary Artery Disease.

Aminuddin A, Samah N, Vijakumaran U, Che Roos N, Mohd Nor F, Wan Razali W Diseases. 2024; 12(8).

PMID: 39195176 PMC: 11353419. DOI: 10.3390/diseases12080177.

The Role of Alarmins in the Pathogenesis of Atherosclerosis and Myocardial Infarction.

Kielbowski K, Skorka P, Plewa P, Bakinowska E, Pawlik A Curr Issues Mol Biol. 2024; 46(8):8995-9015.

PMID: 39194749 PMC: 11352985. DOI: 10.3390/cimb46080532.

References

Shah P . Biomarkers of plaque instability. Curr Cardiol Rep. 2014; 16(12):547. DOI: 10.1007/s11886-014-0547-7. View

Marino-Puertas L, Goulas T, Gomis-Ruth F . Matrix metalloproteinases outside vertebrates. Biochim Biophys Acta Mol Cell Res. 2017; 1864(11 Pt A):2026-2035. DOI: 10.1016/j.bbamcr.2017.04.003. View

Li Y, Li L, Wang K, Wu P, Cui Y . Investigation on Risk Stratification and the Prognostic Value of hs-TnT Combined with MMP-2 in Patients with Acute Coronary Syndrome. Biomed Res Int. 2021; 2021:1040171. PMC: 8632378. DOI: 10.1155/2021/1040171. View

Luchtefeld M, Grote K, Grothusen C, Bley S, Bandlow N, Selle T . Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochem Biophys Res Commun. 2005; 328(1):183-8. DOI: 10.1016/j.bbrc.2004.12.152. View

Kitulwatte I, Pollanen M . A Comparative Study of Coronary Atherosclerosis in Young and Old. Am J Forensic Med Pathol. 2015; 36(4):323-6. DOI: 10.1097/PAF.0000000000000203. View

Nakahara T, Dweck M, Narula N, Pisapia D, Narula J, Strauss H . Coronary Artery Calcification: From Mechanism to Molecular Imaging. JACC Cardiovasc Imaging. 2017; 10(5):582-593. DOI: 10.1016/j.jcmg.2017.03.005. View

Leonarduzzi G, Chiarpotto E, Biasi F, Poli G . 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol Nutr Food Res. 2005; 49(11):1044-9. DOI: 10.1002/mnfr.200500090. View

Wang X, Khalil R . Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol. 2018; 81:241-330. PMC: 5765875. DOI: 10.1016/bs.apha.2017.08.002. View

Mogharrabi M, Rahimi H, Hasanzadeh S, Dastani M, Kazemi-Oskuee R, Akhlaghi S . The effects of nanomicelle of curcumin on the matrix metalloproteinase (MMP-2, 9) activity and expression in patients with coronary artery disease (CAD): A randomized controlled clinical trial. ARYA Atheroscler. 2021; 16(3):136-145. PMC: 7778509. DOI: 10.22122/arya.v16i3.1938. View

10.

Kong D, Kim Y, Kim M, Jang J, Lee S . Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int J Mol Sci. 2018; 19(4). PMC: 5979609. DOI: 10.3390/ijms19041057. View

11.

Owolabi U, Amraotkar A, Coulter A, Singam N, Aladili B, Singh A . Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction. J Thromb Thrombolysis. 2019; 49(2):235-244. PMC: 9012982. DOI: 10.1007/s11239-019-02004-7. View

12.

Murashov I, Volkov A, Kazanskaya G, Kliver E, Savchenko S, Klochkova S . Immunohistochemical Phenotypes of Stable and Unstable Occlusive Atherosclerotic Plaques in Coronary Arteries. Bull Exp Biol Med. 2018; 165(6):798-802. DOI: 10.1007/s10517-018-4268-6. View

13.

Back M, Ketelhuth D, Agewall S . Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis. 2010; 52(5):410-28. DOI: 10.1016/j.pcad.2009.12.002. View

14.

Phatharajaree W, Phrommintikul A, Chattipakorn N . Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007; 23(9):727-33. PMC: 2651917. DOI: 10.1016/s0828-282x(07)70818-8. View

15.

Johnson J . Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther. 2007; 5(2):265-82. DOI: 10.1586/14779072.5.2.265. View

16.

DeVon H, Mirzaei S, Zegre-Hemsey J . Typical and Atypical Symptoms of Acute Coronary Syndrome: Time to Retire the Terms?. J Am Heart Assoc. 2020; 9(7):e015539. PMC: 7428604. DOI: 10.1161/JAHA.119.015539. View

17.

Momi S, Falcinelli E, Petito E, Taranta G, Ossoli A, Gresele P . Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis. Eur Heart J. 2021; 43(6):504-514. DOI: 10.1093/eurheartj/ehab631. View

18.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

19.

Melin E, Dereke J, Hillman M . Galectin-3, metalloproteinase-2 and cardiovascular disease were independently associated with metalloproteinase-14 in patients with type 1 diabetes: a cross sectional study. Diabetol Metab Syndr. 2021; 13(1):118. PMC: 8549137. DOI: 10.1186/s13098-021-00727-3. View

20.

Cui N, Hu M, Khalil R . Biochemical and Biological Attributes of Matrix Metalloproteinases. Prog Mol Biol Transl Sci. 2017; 147:1-73. PMC: 5430303. DOI: 10.1016/bs.pmbts.2017.02.005. View